子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 61 | METHOD OF DIAGNOSING AND TREATING INTERSTITIAL CYSTITIS | US13498411 | 2010-09-23 | US20120177665A1 | 2012-07-12 | Samuel K Chacko |
| A method for diagnosing, or differentially diagnosing, interstitial cystitis (IC) involves detecting or measuring increased expression of a biomarker Endothelin 1 (ET-1) in a biological sample from a mammalian subject, particularly in the urine or urothelial tissue. An increased level of expression of ET-1 above the level of expression in the same sample of a healthy mammalian subject is an indication of a diagnosis of IC. Such diagnosis may further involve identify other clinical symptoms of IC. Additionally the method may use additional biomarkers, such as Hb-EFG, EGF, APF, IL-8, IL-6, and cGMP. Assay methods and diagnostic reagents and kits for such diagnosis are provided. Methods and compositions for treating IC by reducing the action, production or synthesis of ET-1 in the urine or urothelium and/or inhibiting its binding to its ETA and/or ETB receptors are also provided. | ||||||
| 62 | URINARY TRYPSIN INHIBITORS AS DIAGNOSTIC AID FOR INTERSTITIAL CYSTITIS | US13384013 | 2010-07-12 | US20120115174A1 | 2012-05-10 | Michael J. Pugia |
| A method aiding the diagnosis of interstitial cystitis involving the combination of an infection marker and an inflammation marker. More specifically, the method includes correlating the presence of urinary trypsin inhibitors in urine with the absence of traditional infection markers in urine to aid in the diagnosis of interstitial cystitis. The method provides for a differential diagnosis between kidney disease, infection and chronic inflammation with a noninvasive urine test. Assay devices and kits, as well as analyzers and systems are also described that utilize the methodology. | ||||||
| 63 | CELL-BASED DETECTION OF APF THROUGH ITS INTERACTION WITH CKAP4 FOR DIAGNOSIS OF INTERSTITIAL CYSTITIS | US13133244 | 2009-12-10 | US20110244493A1 | 2011-10-06 | David Alan Zacharias; Sonia Lobo Planey |
| An assay system designed to detect a protein biomarker in urine that is diagnostic for interstitial cystitis (IC). The presence of a 9 amino acid glycopeptide, antiproliferative factor (APF), in urine is unique to patients with IC. Urine samples from patients who exhibit symptoms consistent with IC are added to the assay system. Binding of APF to the cytoskeletal associated protein 4 (CKAP4) is positive for the presence of APF in urine and diagnostic for IC. The diagnostic system is a significant and surprising advance in diagnosis of IC and has commercial applications relevant to women and men who suffer from symptoms consistent with IC. | ||||||
| 64 | Fiber-Based Biosensors for Use in Detecting the Presence of a Biologically Active Substance | US13061134 | 2009-08-26 | US20110207168A1 | 2011-08-25 | Konstantin G. Kornev; Aleksey Vertegel; Igor Luzinov |
| Disclosed are fibers comprising one or more electrostatically attached substrates that can be used to determine the presence of a biologically active substance. Further disclosed are substrates comprising the fibers, articles of manufacture comprising the fibers and/or substrates, and methods for detecting the presence of a biologically active substance. | ||||||
| 65 | MONOCLONAL ANTIBODIES AGAINST OSTEOPONTIN | US12983650 | 2011-01-03 | US20110165697A1 | 2011-07-07 | Lucy Liaw; Ah-Kau Ng |
| The present invention relates to reagents and methods for the detection of osteopontin fragments and distinguishing them from each other and from the full-length osteopontin protein. The present invention also relates to assays for the determination of the presence of osteopontin fragments in samples obtained from subjects and, further, the correlation of osteopontin fragment levels fragment levels with disease detection, progression and prognosis. | ||||||
| 66 | METHOD FOR DETECTING THE EXISTENCE OF RENAL CALCULI AND/OR INFLAMMATION OF THE EXCRETORY URINARY TRACTS | US12991344 | 2009-04-28 | US20110117583A1 | 2011-05-19 | Werner Hoffmann |
| A non-invasive method for detecting disease of the excretory urinary tract and presence of renal calculi is provided. According to the method, the presence or concentration of one or more TFF peptides from among TFF1, TFF2, and TFF3 is determined in a urine sample, the presence or concentration being indicative of urinary tract disease or presence of renal calculi. | ||||||
| 67 | Devices for Detecting Renal Disorders | US12852312 | 2010-08-06 | US20110065608A1 | 2011-03-17 | Samuel T. LaBrie; James P. Mapes; Ralph L. McDade; Dominic P. Eisinger; Karri L. Ballard; Michael D. Spain |
| Devices for diagnosing, monitoring, or determining a renal disorder in a mammal are described. In particular, devices for diagnosing, monitoring, or determining a renal disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | ||||||
| 68 | Methods and Devices for Detecting Kidney Damage | US12852295 | 2010-08-06 | US20110065599A1 | 2011-03-17 | Samuel T. LaBrie; James P. Mapes; Ralph L. McDade; Dominic Eisinger; Karri L. Ballard; Michael D. Spain |
| Methods and devices for diagnosing, monitoring, or determining kidney damage in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining kidney damage using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | ||||||
| 69 | Method of treating bladder and lower urinary tract syndromes | US11878317 | 2007-07-23 | US07858312B2 | 2010-12-28 | Debra A. Schwinn |
| The present invention relates to bladder and lower urinary tract syndromes, particularly, irrative symptoms, and to a method of treating same using α1d-adrenergic receptor (α1dAR) antagonists. The invention further relates to a method of screening compounds for their ability to serve as α1dAR selective antagonists. | ||||||
| 70 | DETERMINATION OF THE INTEGRITY OF RNA | US12548226 | 2009-08-26 | US20100057371A1 | 2010-03-04 | Vladimir Denisov |
| Methods, systems, and apparatus make a determination of a level of integrity of a sample of biomolecules. For example, the determination of the integrity of RNA in a sample may be done in a fast and reproducible manner, such that the user can be assured of accuracy of a test (e.g. quantitative polymerase chain reaction qPCR) on the sample and compare results of different samples. The determination of integrity of an RNA sample is performed by comparing a size profile to reference size profiles (degradation standards) obtained from degradation over different lengths of times. As the reference scale of the level of integrity is derived from the actual degradation that occurs in a sample, high accuracy, reproducibility, and efficiency is provided. | ||||||
| 71 | Method for Examing Interstitital Cystitis | US11596867 | 2005-05-19 | US20080213800A1 | 2008-09-04 | Tetsuo Yamada; Haruhisa Mita; Sadao Kuromitsu; Hiroyuki Yokota; Shuji Morita; Masashi Hiramoto; Masatoshi Yuri |
| It has been found that the urine from an IC patient shows a high value in amount and the existence of activity of an azurophilic granular substance, thereby to establish a method for examining IC. The present invention relates to a method for examining interstitial cystitis using the kinetics of an azurophilic granular substance in urine as a marker. Also, the present invention relates to a kit for examining interstitial cystitis for use in the examination method, a use of an azurophilic granular substance as a test marker for examining interstitial cystitis or evaluating pharmacological effects of a drug, and a method for examining therapeutic effects on a patient with interstitial cystitis using an azurophilic granular substance as a marker. | ||||||
| 72 | Antibody to bladder cancer nuclear matrix protein and its use | US11090289 | 2005-03-28 | US07258991B2 | 2007-08-21 | Robert H. Getzenberg |
| Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention. | ||||||
| 73 | Non-invasive diagnostic method for interstitial cystitis and bladder cancer | US959263 | 1997-10-28 | US6008003A | 1999-12-28 | Mary Haak-Frendscho; Angela J. Okragly; Andrew L. Niles; Ricardo Saban |
| Disclosed is a method of diagnosing or monitoring interstitial cystitis or bladder cancer in a mammal. The method comprises analyzing urine of the mammal for the concentration of a urine-soluble protein selected from the group consisting of neurotrophin-3, nerve growth factor, glial cell line-derived neurotrophic factor, tryptase, and combinations thereof. | ||||||
| 74 | Bladder nuclear matrix proteins, polynucleotide sequences encoding them, and their use | US742850 | 1996-11-01 | US5866535A | 1999-02-02 | Robert H. Getzenberg; Robert H. Bahnson |
| Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention. | ||||||
| 75 | Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases | US456855 | 1995-06-01 | US5591830A | 1997-01-07 | Morgan Van Aken; Stefan L. Paskell |
| Isolated complexes (which include basement membrane components), antibodies to such complexes or polypeptide constituents thereof, and methods for detecting such complexes or constituents are disclosed. Detection of such complexes in a biological sample by immunological and non-immunological methods allows the diagnosis of a variety of diseases, including cancers, collagen degenerative diseases, and hepatitis. Suitable biological samples include urine, cervical secretions, bronchial aspirates, sputum, saliva, feces, serum, synovial fluid, and cerebrospinal fluid. | ||||||
| 76 | Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases | US457285 | 1995-06-01 | US5591595A | 1997-01-07 | Morgan Van Aken; Stefan L. Paskell |
| Isolated complexes (which include basement membrane components), antibodies to such complexes or polypeptide constituents thereof, and methods for detecting such complexes or constituents are disclosed. Detection of such complexes in a biological sample by immunological and non-immunological methods allows the diagnosis of a variety of diseases, including cancers, collagen degenerative diseases, and hepatitis. Suitable biological samples include urine, cervical secretions, bronchial aspirates, sputum, saliva, feces, serum, synovial fluid, and cerebrospinal fluid. | ||||||
| 77 | Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases | US178219 | 1994-01-06 | US5512657A | 1996-04-30 | Morgan Van Aken; Stefan L. Paskell |
| Isolated complexes (which include basement membrane components), antibodies to such complexes or polypeptide constituents thereof, and methods for detecting such complexes or constituents are disclosed. Detection of such complexes in a biological sample by immunological and non-immunological methods allows the diagnosis of a variety of diseases, including cancers, collagen degenerative diseases, and hepatitis. Suitable biological samples include urine, cervical secretions, bronchial aspirates, sputum, saliva, feces, serum, synovial fluid, and cerebrospinal fluid. | ||||||
| 78 | Methods of using pigment epithelium derived factor (PEDF) for the treatment and prevention of agent-induced gonadal or uterine toxicity | US15129007 | 2015-03-30 | US10130682B2 | 2018-11-20 | Ruth Shalgi; Dana Chuderland; Hadas Bar-Joseph; Keren Goldberg; Irit Ben-Aharon; Salomon M. Stemmer |
| A method of treating or preventing gonadal or uterine toxicity induced by an agent in a subject is provided. Accordingly there is provided a method comprising administering to a subject a therapeutically effective amount of pigment epithelium-derived factor (PEDF), thereby treating or preventing the gonadal toxicity induced by the agent. Also provided is, a method comprising determining gonadal function in a subject; and administering to the subject a therapeutically effective amount of PEDF, thereby treating or preventing the gonadal toxicity induced by the agent. Also provided is a PEDF for use in the treatment or prevention of gonadal toxicity induced by an agent in a subject. Also provided are cell culture, a medium, a kit and method for improving oocyte quality ex-vivo. | ||||||
| 79 | Treating and preventing disease with TMA and TMAO lowering agents | US15610145 | 2017-05-31 | US10117879B2 | 2018-11-06 | Stanley L. Hazen |
| Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent. | ||||||
| 80 | Methods and Devices for Detecting Diabetic Nephropathy and Associated Disorders | US15675367 | 2017-08-11 | US20170370947A1 | 2017-12-28 | Samuel T. LaBrie; James P. Mapes; Ralph L. McDade; Dominic Eisinger; Karri L. Ballard |
| Methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | ||||||
QQ群二维码
意见反馈
意见反馈